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SUMMARY
Glutamine-synthetase (GS), the glutamine-synthe-
sizing enzyme from glutamate, controls important
events, including the release of inflammatory medi-
ators, mammalian target of rapamycin (mTOR)
activation, and autophagy. However, its role in
macrophages remains elusive. We report that phar-
macologic inhibition of GS skews M2-polarized
macrophages toward the M1-like phenotype, char-
acterized by reduced intracellular glutamine and
increased succinate with enhanced glucose flux
through glycolysis, which could be partly related
to HIF1a activation. As a result of these metabolic
changes and HIF1a accumulation, GS-inhibited
macrophages display an increased capacity to
induce T cell recruitment, reduced T cell suppres-
sive potential, and an impaired ability to foster
endothelial cell branching or cancer cell motility.
Genetic deletion of macrophagic GS in tumor-
bearing mice promotes tumor vessel pruning,
vascular normalization, accumulation of cytotoxic
T cells, and metastasis inhibition. These data iden-
tify GS activity as mediator of the proangiogenic,
immunosuppressive, and pro-metastatic function
of M2-like macrophages and highlight the possibi-
lity of targeting this enzyme in the treatment of
cancer metastasis.
INTRODUCTION
Macrophages are able to display different activation states in
response to specific stimuli. Quiescent macrophages (M0) can
be activated by interferon-g (IFNg) and Toll-like receptor (TLR)
agonists toward an inflammatory (M1-like) phenotype, thus
developing pro-inflammatory microbicidal and tumoricidal
properties. However, under interleukin-4 (IL-4), IL-13, and
IL-10 (M2-like activation), macrophages suppress inflamma-
tory and adaptive Th1 responses by producing anti-inflamma-
tory factors (IL-10, transforming growth factor b [TGF-b], and
IL-1 receptor antagonist [IL-1Ra]), scavenging debris and pro-
moting angiogenesis, tissue remodeling, and repair (Locati
et al., 2013; Martinez et al., 2006). Lately, it has become
evident that this phenotypic response to their microenviron-
ment is transcriptionally and metabolically regulated (McGet-
trick and O’Neill, 2013; O’Neill and Hardie, 2013). Specific
metabolic features have been associated with M1-like macro-
phages displaying enhanced glycolysis and reduced oxida-
tive phosphorylation in contrast with more oxidative M2-like
macrophages (Biswas and Mantovani, 2010). However, the
functional valorization of these different metabolic reactions
is far from being completed. Elucidation of these critical path-
ways might be significant in tumor-associated macrophages
(TAMs), which can acquire pro-metastatic and angiogenic
properties at the tumor site. Recent studies point to the
role of environmental factors in primary tumors and how the
targeting of these signals can suppress the immunosuppres-
sive, pro-angiogenic, and pro-metastatic functions of TAMs
(Casazza et al., 2013; Colegio et al., 2014; Wenes et al., 2016).
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Glutamine synthetase (GS) is a key enzyme involved in
nitrogen metabolism, acid-base homeostasis, and cell signaling
across multiple species of prokaryotes and eukaryotes (Eisen-
berg et al., 2000). One of the main roles of GS in vertebrates is
to produce glutamine from glutamate and ammonia, which are
toxic to the CNS (Butterworth, 2003; Liu et al., 2013; Olney,
1990). Moreover, a continuous supply of glutamine is required
for several physiological processes, including synthesis of gluta-
mate and gamma-aminobutyric acid (GABA), synthesis of pro-
teins, and osmoregulation (Norenberg et al., 2007). Expression
of GS has been noted in different tumor cells, macrophages,
and adipocytes (Chre´tien et al., 2002; Hadden et al., 1997;
Kocher et al., 2000; Kung et al., 2011). Interestingly the gluta-
mine-producing activity of GS has recently been associated
with important signaling mechanisms. GS activity inhibits the
mammalian target of rapamycin (mTOR) pathway and induces
autophagy in B cells (van der Vos et al., 2012). We have recently
found that GS is expressed at later stages of adipocyte differen-
tiation in a glucocorticoid-independent manner and desensitizes
mature adipocytes to proinflammatory insults by raising intracel-
lular glutamine levels, demonstrating amechanism by which GS,
through glutamine production, controls adipocyte response to
pro-inflammatory stimuli (Palmieri et al., 2014). In murine micro-
glia, GS activity controls the response to lipopolysaccharide
(LPS) (Palmieri et al., 2017). GS is also capable of promoting
T cells with high Foxp3 expression and regulatory properties in
regulatory T cells (Tregs) (Metzler et al., 2016), whereas glutami-
nolysis induces an inflammatory anti-tumor (Th1) response in
effector T cells and represses the formation of Treg cells (Klysz
et al., 2015). Finally, glutamine consumption is increased during
classical macrophage activation (Curi et al., 2007; Murphy and
Newsholme, 1998).
In the present study, we characterize the role of GS in
modulating macrophage skewing toward the M2 phenotype.
We show that GS expression primes primary human mono-
cytes into M2 macrophages, whereas GS inhibition switches
their phenotype toward a more M1-like phenotype through a
specific metabolic rewiring involving succinate accumulation.
The enhanced production of succinate is a critical regulator
of the pro-inflammatory response, both through the inhibition
of anti-inflammatory gene expression and via hypoxia induc-
ible factor (HIF)-1a stabilization (Mills et al., 2016). Consis-
tently, GS inhibition in macrophages translates into a strong
functional impairment in terms of in vitro T cell recruitment
and angiogenesis. Macrophage-specific knockout of GS re-
sults in a marked reduction in metastasis formation in mice.
These findings establish GS as a main metabolic regulator of
inflammation by modulating glutamine levels. Furthermore, se-
lective targeting of GS in macrophages might effectively
contrast metastatic processes, increasing the survival of ma-
lignant cancer patients.
RESULTS
GS Is Expressed in Alternatively Activated (M2-like)
Macrophages
To evaluate the role of GS in the polarization of blood-derived
human macrophages, we first tested GS protein expression in
primary human resting macrophages (M0/resting), those with a
proinflammatory phenotype (M1) induced by LPS/IFNg, and
with the alternatively activated phenotype (M2) elicited with
IL-4 and IL-10, alone or in combination, or otherwise with a com-
bination of the anti-inflammatory cytokines IL-4 and IL-13with an
overlapping function (Huang et al., 2015).
We found that GS protein was barely detected in M1 cells and
more expressed in M2 cells (Figures 1A and 1B), particularly in
IL-10-stimulated cells over all other anti-inflammatory stimuli,
as detected through western blotting (Figure 1A). We then
evaluated GS gene expression and activity levels during IL-10
stimulation of (M0) monocyte-derived macrophages (IL-10 mac-
rophages in short). Two hours before stimulation with IL-10, cells
were primed (or not) with the GS inhibitor methionine sulfoximine
(MSO) at a concentration of 1 mM (MSO/IL-10 macrophages in
short). Importantly, MSO is not toxic up to 5 mM (Figure S1).
GS expression was increased in IL-10 andMSO/IL-10 compared
with M0 cells (Figure 1C). Following GS expression, GS activity
was also increased in IL-10-stimulated compared with M1 cells
(Figure 1D). In line with this finding, intracellular glutamine levels
were significantly higher in IL-10-derived M2 compared with M0
macrophages at 24 and 48 hr (Figure 1E). Treatment with the GS
inhibitor MSO reduced intracellular glutamine levels at all times
(Figure 1E). This indicates that the effect of GS inhibition is linked
to the decrease in the intracellular levels of glutamine in IL-10
macrophages.
MSO Treatment of M2 Macrophages Promotes
Succinate Accumulation and Glucose-Dependent
Metabolism
Having established that GS is enriched in IL-10 macrophages,
we aimed to characterize metabolism in IL-10-treated macro-
phages and the consequences of GS inhibition on these meta-
bolic features (O’Neill and Pearce, 2016). Metabolites, together
with 13C incorporation levels from [U-13C]-glutamine or [U-13C]-
glucose, were measured in LPS/IFNg, IL-10, and MSO/IL-10
macrophages.
MSO treatment of IL-10 macrophages induces a significant
rewiring of macrophage metabolism. As expected, MSO/IL-10
macrophages displayed much higher levels of glutamate
compared with IL-10-treated macrophages. This was accom-
panied by a significant increase in the levels of succinate
(Figure 2A), but not of other tricarboxylic acid (TCA) cycle inter-
mediates (data not shown), and GABA, similar to LPS/IFNg
macrophages (Figure 2A). Interestingly, 13C labeling experi-
ments revealed that MSO treatment causes a significant shift
from glutamine to glucose utilization for glutamate and TCA in-
termediate synthesis (Figures 2B–2F), as demonstrated by the
consistent drop in 13C labeling from glutamine and the increase
in 13C labeling from glucose in TCA cycle intermediates, with the
exception of succinate (Figure 2G), in which there is a significant
enrichment from 13C glutamine. However, glutamine uptake is
not reduced, as also suggested by upregulation of the glutamine
transporter LAT1 in MSO/IL-10 compared with IL-10 macro-
phages (Figure 2H), but is sustained and rerouted to succinate
synthesis, probably through the GABA shunt. Additionally,
the slight 13C enrichment in M+3 malate and citrate from
glucose (Figure S2) clearly points to a small but significant
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reprogramming of pyruvate metabolism toward oxaloacetate
through pyruvic carboxylase (PC) (Fan et al., 2010; Le et al.,
2012).
GS Inhibition Blocks M2-like Skewing and Promotes an
M1-like Phenotype
Because succinate accumulation, increased glucose utilization,
and PC activation are all features typical of classically activated
macrophages, we investigated the functional consequences of
GS inhibition on the differentiation state of primary humanmono-
cyte-derived macrophages primed in culture toward an anti-in-
flammatory phenotype. As expected, the M2 macrophage
marker CD163 was strongly induced and pronouncedly ex-
pressed on the surface of macrophages by IL-10 (Figure 3A).
GS inhibition strongly reduced IL-10-mediated upregulation of
CD163 in macrophages (Figures 3A–3C). In IL-10-stimulated
cells, expression of the costimulatory molecule CD80 was
almost absent (Figure 3A) compared with expression of the
same marker in endotoxin-stimulated cells (M1) (Figures 3A
and 3B). Treatment with IL-10 in the presence of MSO induced
the M1 phenotype in macrophages, as indicated by the strong
appearance and upregulation of CD80 concomitant with disap-
pearance of CD163 (Figure 3D).
Based on these results, we assessed the influence of GS on
genes that are differentially expressed in M1 and M2 macro-
phages. GS inhibition in IL-10-stimulated macrophages upregu-
lated the expression of genes preferentially found in M1 macro-
Figure 1. IL-10 Macrophages Display GS
Expression and Activity
(A and B) GS and b-actin immunoblot (A) and
densitometric levels (B) in human CD14, CD14+
cells (monocytes), resting (M0, macrophage
colony stimulating factor [MCSF]), and differently
polarized monocytes-derived macrophages (LPS/
IFNg, IL-4, IL-10, IL-13, and a combination of
those, with M-CSF) following 24 hr of activation
(n = 3).
(C) GS expression levels in resting M0, IL-10, and
MSO/IL-10 macrophages following 16 hr of acti-
vation with and without 2 hr of pre-incubation with
MSO (n = 3).
(D) GS protein activity levels in resting (M0), LPS/
IFNg, and IL-10 macrophages following 24 hr of
activation (n = 4).
(E) LC-MS/MS quantification of intracellular
glutamine in resting (M0), IL-10, and MSO-treated
IL-10 6, 24, and 48 hr after treatment (n = 4).
Data are means ± SEM. Western blots are repre-
sentative of 3 independent experiments. *p < 0.05,
**p < 0.001, ***p < 0.0001.
phages, such as TNF-a and NOS2 and, to
a higher extent, CXCL9 and CXCL10 (Fig-
ure 3E; Figure S1B). MSO strongly pre-
vented the induction of M2-specific
markers upon IL-10 stimulation, such as
MSR1 (CD204) and MRC1 (CD206),
CCL17, and CCL18 (Figure 3E; Fig-
ure S1B). These data indicate that GS
plays a positive role in M2 macrophage polarization and that
GS blockade hinders the expression of M2 markers, whereas it
promotes M1 markers.
To ascertain whether glutamate accumulation alone could be
responsible for programming expression of specific markers of
M1 macrophages, we treated IL-10 macrophages with the
permeable dimethylglutamate (DMG). As shown in Figure 3F, in-
cubation with 5 mM DMG in M2 macrophages is sufficient to
induce a marked increase in M1 markers (Figure 3F) without
influencing M2 markers (data not shown).
GS Inhibition Leads to HIF1a Activation
Having established that GS inhibition promotes an M1-like
phenotype in macrophages in which the levels of succinate are
increased, we then investigated the molecular mechanisms
behind this functional reprogramming. Because succinate is
known to stabilize HIF1a activity (Tannahill et al., 2013), we spec-
ulated that GS inhibition (and succinate accumulation) might
promote a classical M1 phenotype through HIF1a activation
(Takeda et al., 2010).
First of all, we assessed HIF1a transcriptional activity by ex-
pressing an inducible HIF-responsive firefly luciferase reporter
in LPS/IFNg, IL-10, and MSO/IL-10 macrophages. Luciferase
activity was maximal in LPS/IFNg, as expected, and very low
in IL-10-treated macrophages (Figure 4A). MSO treatment
completely reversed this activity in IL-10 macrophages because
these cells exhibited luciferase signals comparable with
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LPS/IFNg macrophages. Inhibition of HIF1a activity in LPS/IFNg
and MSO/IL-10 cells through acriflavine treatment lowered the
luciferase reporter signal to the levels of resting (M0) and IL-10
macrophages (Figure 4A). In line with this finding, the HIF1a pro-
tein levels in MSO/IL-10 and LPS/IFNg were higher compared
with IL-10 macrophages (Figure 4B).
Additionally, HIF1a inhibition by acriflavine treatment in MSO/
IL-10 macrophages rescued the M2- to M1-like phenotype
switching, as demonstrated by the decreased expression of
markers typically expressed in classically activated macro-
phages, such as TNF-a, CXCL10, and inducible nitric oxide syn-
thase (NOS2) (Figure 4C), and the concomitant increase of
markers expressed in IL-10 macrophages, such as CCL17,
MRS1, CCL18, and MRC1 (Figure 4C). Overall, these data sup-
port the idea that GS inhibition blocks the M2 skew by IL-10
and promotes anM1 phenotype, at least in part, via HIF1a, which
can be possibly stabilized by succinate accumulation (Mills et al.,
2016).
Starvation ofM2Macrophages Increases GS Expression
Since GS is known to respond to conditions of nutrient depriva-
tion (van der Vos et al., 2012), we wanted to ascertain whether
Figure 2. GS Inhibition Modifies Metabolite Levels in IL-10 versus LPS/IFNg Macrophages
(A) Evaluation of glutamate, GABA, and succinate in IL-10,MSO/IL-10, and LPS/IFNg versus resting (ctrl, 100%)macrophages (n = 6) following 24 hr of activation.
(B–G) Evaluation of the [U-13C]-glutamine-derived (right) and [U-13C]-glucose-derived (left) carbon incorporation levels into the TCA intermediates citrate (B),
glutamate (C), 2 oxoglutarate (D), malate (E), fumarate (F), and succinate (G) in resting (M0), IL-10, and MSO-treated IL-10 versus LPS/IFNg macrophages
following 24 hr of activation (n = 4).
(H) LAT1 expression levels in resting M0, IL-10, and MSO/IL-10 macrophages following 16 hr of activation with and without previous MSO addition (n = 3).
Data are means ± SEM. *p < 0.05, **p < 0.001, ***p < 0.0001.
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this was the case in macrophages. As starvation enhanced GS
expression in both M0 and IL-10 macrophages (Figure 5A), we
hypothesized that starvation could promote M2 polarization by
promoting GS expression irrespective of IL-10 treatment. With
this aim, we cultured M0 macrophages in regular rich medium
(2 mM glutamine and 11 mM glucose) or in deprived medium
(2 mM glucose and 0.3 mM glutamine) without any additional
stimulus and measured M2 and M1 markers. Expression of M2
markers was enhanced in starved compared with normally
Figure 3. GS Inhibition Modifies Polarization
of IL-10 Macrophages
(A) Flow cytometric quantification of the percentage
of CD80+ and CD163+ cells after IL-10 treatment in
the absence or presence of MSO versus LPS/IFNg
treatment following 24 hr of activation (n = 4).
(B and C) FACS quantification of CD80 (B) and
CD163 (C) levels in IL-10 and MSO-treated IL-10
versus LPS/IFNg macrophages as above.
(D) FACS dot plots depicting CD80 and CD163
modulation following MSO treatment in IL-10
macrophages.
(E) qRT-PCR quantification of M1 or M2 markers in
macrophages. Top: fold increase of TNF-a, CXCL9,
CXCL10, and NOS2 mRNA in IL-10 and MSO-
treated IL-10 (n = 3). Bottom: fold reduction of
MSR1, MRC1, CCL17, and CCL18 mRNA in IL-10
and MSO-treated IL-10 macrophages following
24 hr of activation with and without previous MSO
addition (n = 3).
(F) qRT-PCR quantification of M1 markers in mac-
rophages with DMG. Shown is the fold increase of
CD86, TNF-a, CD80, and CXCL10 mRNA in IL-10
macrophages with and without 2 hr of pre-incuba-
tion with 5 mM DMG.
Data are means ± SEM. *p < 0.05. ***p < 0.0001.
grown M0 macrophages (Figure 5B)
without any change in M1 markers (data
not shown). To shed light on the role of
GS expression under starved conditions,
we measured the levels of extracellular
glutamine in starved M0 compared with
LPS/IFNg macrophages. In rich medium,
glutamate uptake in M0 macrophages
parallels that displayed by LPS/IFNg,
whereas extracellular glutamine levels dis-
plays differences in M0 compared with
LPS/IFNg macrophages, which reached
statistical significance at 72 hr (Figure 5C).
Under starved conditions, extracellular
levels of glutamate markedly decreased
under both conditions, whereas, under
starvation, glutamine levels significantly
increased at 48 hr and even more at 72 hr
in M0 compared with LPS/IFNg macro-
phages, in which glutamine levels did not
change (Figure 5C). This suggests that
glutamine produced by the activity of GS
in M0 macrophages might be secreted
into spent medium, and this is also corroborated by the
increased expression levels of the cellular glutamine trans-
porters ASCT2 and LAT1 (Figure 5D).
GS-Inhibited Macrophages Induce Lymphocyte
Recruitment and Inhibit T Cell Suppression, Endothelial
Cell (EC) Capillary Formation, and Cancer Cell Motility
Macrophages in their altered form are one of themajor players to
cause systemic fault of effector T cell functions (Kreider et al.,
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2007). We then tested the relevance of GS inhibition in M2 mac-
rophages for T cell suppression and migration. After MSO was
washed out, resting M2 and M2/MSO macrophages were co-
cultured with autologous CD4+ and CD8+ T cells. IL-10-derived
M2 macrophages stimulated for 24 hr had the highest ability to
suppress the proliferation of cocultured CD4+ and CD8+ T cells
Figure 4. GS Inhibition Stabilizes HIF1a
Activity
(A) Evaluation of HIF1a transcriptional activity in
resting (M0) and IL-10 versus LPS/IFNg macro-
phages after 16 hr of stimulation with and/or
without previous MSO and acriflavine (ACF)
addition (n = 3).
(B) Western blotting and densitometric analysis of
HIF1a protein inM0, IL-10, andMSO-treated IL-10
versus LPS/IFNg macrophages after 16 hr of
stimulation (n = 3).
(C) qRT-PCRquantification ofM1 orM2markers in
macrophages following HIF1a inhibition. Top: fold
change of TNF-a, NOS2, and CXCL10mRNA in IL-
10 stimulated macrophages with and/or without
previous MSO and ACF addition (n = 3). Bottom:
fold change of MSR1, MRC1, CCL17, and CCL18
mRNA levels in macrophages as above (n = 3).
Data are means ± SEM. *p < 0.05, ***p < 0.0001.
(Figures 6A and 6B). Priming with MSO
blunted the T cell-suppressive phenotype
of M2 macrophages because CD4+ and
CD8+ T cell proliferation was partly
rescued; however, this rescue was statis-
tically significant with CD8+ T cells only
(Figures 6A and 6B). Nevertheless, the
proliferation index (PI, the number of
divisions divided by the number of cells
that underwent division) significantly
increased in both CD4+ and CD8+ cells
when cultured with MSO/IL-10 versus
IL-10 macrophages (Figure S3). We also
evaluated the activation marker CD69 in
T cell populations after coculture. We
show that MSO/IL-10 macrophages
induced a significant upregulation of
CD69 expression on the surface of both
CD4+ and CD8+ T cells compared with
IL-10-stimulated macrophages and M0
resting cells (Figures 6C and 6D).
To evaluate the extent of adhesion and
chemotaxis of T cells, CD8+ lymphocytes
were cultured either alone or with,
respectively, LPS/IFNg, IL-10, and
MSO/IL-10 macrophages and stimulated
with the chemoattractant CXCL10. The
presence of the chemokine or of M1
macrophages elicited their chemotaxis
through a 5-mm pore membrane, at vari-
ance with IL-10-treated macrophages
and the condition without macrophages
() (Figure 6E). Upon MSO treatment, IL-10 macrophages re-
gained the ability to promote migration and recruitment of
T cells (Figure 6E).
Based on the previous findings, we next assessed the network
of capillary formation promoted by M2 macrophages under con-
ditions of GS inhibition. Compared with IL-10 macrophages,
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MSO/IL-10 cells displayed a reduced ability to promote capillary
formation, indicating that theMSO treatment is able to reduce the
angiogenic phenotype of IL-10 macrophages (Figure 6F). Given
the ability of M2 macrophages to sustain cancer cell motility
(Joyce andPollard, 2009), we set up a systemwherewe assessed
cancer migration trough 8-mm pores in the presence of IL-10
versusMSO/IL-10macrophages. Consistentwith the observation
that GS inhibition prevents M2 features, cancer cell migration in
the presence of MSO/IL-10 macrophages was 56% inhibited
compared with the condition where IL-10-stimulated M2-like
macrophages were present on the Transwell (Figure 6G). In
line with a more M1-like phenotype, MSO/IL-10 macrophages
behaved similarly to LPS/IFNg macrophages (Figure 6G).
Hence, GS activity in IL-10-stimulated, M2-like macrophages
is required to suppress CD4+ and CD8+ T cell proliferation and
limit CD8+ cell migration, whereas it promotes EC and cancer
cell migration.
GS Deficiency in Tumor-Associated Macrophages
Prevents Metastasis
To translate our findings in vivo, we specifically knocked
out GS in macrophages upon administration of tamoxifen in
Figure 5. Starvation Enhances GS Expression in IL-10-Polarized Macrophages
(A) Western blotting and densitometric analysis of GS in resting (M0) and IL-10-treated macrophages in rich and starved medium after 60 hr of culture. Shown are
representative lanes of the same western blot run and exposure. Data are means ± SEM. *p < 0.05, **p < 0.001 versus M0.
(B) qRT-PCR quantification of M2 markers under starved conditions. Shown are fold changes of MSR1, MRC1, CD209, CD163, and CCL18 mRNA in M0
macrophages in rich versus starved medium after 36 hr of culture (n = 3).
(C) Extracellular levels of glutamate and glutamine in rich and starved medium. Shown is quantification of glutamate and glutamine at 24, 48, and 72 hr of
starvation (n = 3). Data are means ± SEM. *p < 0.05, **p < 0.001, ***p < 0.0001 in 72-hr- compared with 24-hr-starved cells. #p < 0.05 in M0 versus LPS/IFNg-
treated cells.
(D) qRT-PCR quantification of GS and the glutamine transporters under rich and starved conditions. Shown are fold changes of GS, ASCT2, and LAT1 mRNA in
M0 macrophages in rich versus starved medium after 36 hr of culture (n = 3).
Where not indicated otherwise, data are means ± SEM. *p < 0.05, **p < 0.001.
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GS-floxed mice expressing a tamoxifen-induced Cre under
the macrophage promoter Csf1r, thus obtaining GS condi-
tional knockout (cKO) mice (Experimental Procedures). After
checking for macrophage-specific GS deletion (Figure 7A)
and their metabolic features under stimulation (Figure S4),
we implanted Lewis lung carcinoma (LLC) cells subcutane-
ously and monitored tumor growth. Although the tumor vol-
umes and weights were always similar (Figures 7B and 7C),
metastases in GS cKO versus GS wild-type (WT) mice were
decreased 2-fold (Figure 7D). We then evaluated the features
of the TAM infiltrate by fluorescence-activated cell sorting
(FACS) and analyzed the expression of the M1-like marker ma-
jor histocompatibility complex class II (MHC class II) and the
M2-like marker CD206 (MRC1) on the cell membrane of F4/
80+ cells (Laoui et al., 2014). Despite the overall macrophage
abundance, in the tumor being comparable in both genotypes
(Figure 7E; Figures S5A and S5B), we confirmed that GS cKO
TAMs were prevalently MHC class IIhigh and CD206low (M1-
like) compared with the WT controls that displayed mostly
an MHC class IIlow and CD206high (M2-like) phenotype (Figures
7F and 7G). Furthermore, GS cKO TAMs displayed higher
levels of intracellular glutamate and succinate but lower levels
of glutamine, as shown by MSO/IL-10-treated macrophages
(Figures 7H–7J). Finally, reduced expression of the M2-spe-
cific markers Arg1, Mrc1, Ccl17, and Ccl22 further confirmed
that GS KO TAMs were skewed away from the M2-like pheno-
type (Figures 7K–7N).
To validate our in vitro observation that GS inhibition leads to a
less immunosuppressive phenotype, we quantified intratumoral
T cells in GS cKO versus WT mice. Although CD4+ T cells were
comparable in both genotypes (Figure S5C), cytotoxic CD8+
T cells were increased by 75% upon GS deletion in TAMs
(Figure 7O).
We also studied the tumor vasculature, and, according to the
shift in macrophage phenotype, we found a decrease in CD31
staining in tumors from GS cKO versus WT mice (Figures 7P
and 7Q). However, tumor vessels in GS cKO mice displayed
increased functionality and vascular integrity, as indicated,
respectively, by reduced tumor hypoxia and decreased accumu-
lation of leaked red blood cells in the perivascular space (Figures
7R–7U). To exclude any artifacts derived from the expression
of Cre in KO TAMs only, we compared GS cKOmice with hetero-
zygous controls (carrying the Cre transgene as well) and
confirmed all of the key features described above (Figure S6).
Altogether, these data demonstrate that the inhibition of GS in
TAMs hinders their angiogenic, immunosuppressive, and pro-
metastatic potential.
Figure 6. GS Targeting inMacrophages Prevents T Cell Suppression
and Inhibits Endothelial Capillary Network Formation
(A and B) T cells labeled with cell trace violet (CTV) were stimulated with or
without autologous macrophages in different ways. Five days later, the per-
centage of CTV-low cells, measured by flow cytometry, was used as a mea-
sure of CD4+ (A) and CD8+ (B) proliferation (n = 4).
(C and D) Evaluation of CD69 protein, expressed asmean fluorescence intensity
(MFI), was determined by flow cytometry on the surface of responder CD4+ (C)
and CD8+ T cells (D) after coculture with or without macrophages (n = 3).
(E) CD8+ T cell recruitment by IL-10 and MSO-treated IL-10 macrophages
versus LPS/IFNg macrophages; the migration of T cells cultured without
macrophages () in the presence of CXCL10 was used as a positive ctrl (n = 2).
(F) Quantification of the endothelial capillary network in the presence of
macrophages pretreated for 24 hr with IL-10 or MSO/IL-10 after 4 hr of incu-
bation with HUVEC cells (n = 8).
(G) Evaluation of cancer cell migration through a Matrigel-coated micropore
filter in the absence () or presence of LPS/IFNg, IL-10, and MSO/IL-10
prestimulated macrophages after 24 hr of incubation (n = 6).
Data are means ± SEM. *p < 0.05, **p < 0.001, ***p < 0.0001 versus IL-10.
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DISCUSSION
TAMs are known to actively participate in themetastatic process
by contributing to different steps in the metastatic cascade
(Pollard, 2004). Indeed, TAMs do not only allow the tumor to
escape the immune system but also promote angiogenic and
lymphangiogenic sprouting, allowing cancer cells to escape
through the vascular and lymphatic system, and, importantly,
contribute to the formation of discontinuous, poorly covered,
and leaky blood vessels that, because of their poor functionality,
will not be able to restore oxygenation (Casazza et al., 2013;
Condeelis and Pollard, 2006; Rolny et al., 2011). The lack of ox-
ygen (hypoxia) and transient vascular permeability ultimately
favor metastasis (Casanovas et al., 2005; Kerbel, 2005; Mazzone
et al., 2009). It follows that antibodies blocking CSF1R, the re-
ceptor for the most relevant macrophage growth factor, CSF1,
reduces circulating cancer cells and metastasis (Ries et al.,
2014; Wyckoff et al., 2004).
Recently, metabolism has been highlighted as an important
mediator of macrophage function through the discovery of the
mechanisms that, behind these metabolic changes, strongly
affect immune function (Galva´n-Pen˜a and O’Neill, 2014), poten-
tially modulating cancer development and metastasis formation.
Here we identify a metabolic mechanism in macrophages that
promotes protumoral and metastatic activities. GS activity and
increased glutamine production provide metabolic conditions
leading to the accumulation of M2-like, pro-metastatic macro-
phages (Figure S7). Besides its channeling into the TCA cycle,
glutamine contributes to nucleotide and uridine diphosphate
N-acetylglucosamine (UDP-GlcNAc) synthesis for support of
protein folding and trafficking (Wellen and Thompson, 2012). In
M2 macrophages, the glutamine route toward UDP-GlcNAc is
particularly enhanced (Jha et al., 2015) because the molecule
represents a building block for the synthesis of glycosylation
moieties of lectin/mannose receptors, which, in their highly gly-
cosylated form, are among the most typical M2 polarization
markers (Sica and Mantovani, 2012). GS may then be crucial
to sustain the M2 phenotype.
The relevance of GS in IL-10-stimulated macrophages is
evident from the profound metabolic changes following GS inhi-
bition and the subsequent functional deviation. Indeed, MSO
treatment in IL-10 macrophages produces a strong intracellular
accumulation of glutamate, which is probably a result of the
cell’s inability to synthesize glutamine and remove ammonia.
We show that abnormal glutamate alone is capable of skewing
IL-10 macrophages toward a proinflammatory phenotype. How-
ever, MSO-inhibitedmacrophages display all the typical features
of M1-like macrophages in which HIF1a is stabilized, such as
enhanced glycolysis and increased M1 marker expression and
typical functional behavior (Corcoran and O’Neill, 2016). Our re-
sults support a role of succinate as a pro-inflammatory metabo-
lite that accumulates from glutamine through the GABA shunt.
Because succinate is a critical regulator of the pro-inflammatory
response, both through the inhibition of anti-inflammatory gene
expression and via HIF1a stabilization (Mills et al., 2016); accu-
mulation of this metabolite under conditions of GS inhibition
might conceivably relate to the measured increased HIF1a
activity. However, given the spectrum of metabolic changes
described here, other HIF1-independent mechanisms can un-
derline this phenotypic change in GS-inhibited macrophages.
The in vitro data are confirmed in an in vivo murine model of
conditional GS deletion in TAMs in which metastasis formation
is significantly reduced compared with control mice. Although
restricted to a single tumor type, these results strongly support
the idea that GS activity is important for the proangiogenic,
immunosuppressive, and pro-metastatic function of M2-like
macrophages. Accumulation of MHC class IIhigh CD206low M1-
like macrophages following genetic deletion of GS is associated
with a reduced metastatic burden (Figure 7) without altering the
size of the primary tumor. This phenomenon can be explained by
the contribution of TAMs to promoting distant cancer cell
dissemination more than their relevance to tumor growth (Qian
et al., 2015). However, such an effect on metastasis can be
also indirect and, because of tumor vascular normalization,
linked to reduced hypoxia and vessel permeability, in line with
our previous reports (Leite de Oliveira et al., 2012; Mazzone
et al., 2009; Rolny et al., 2011). Obviously, increased immunosur-
veillance as suggested by augmented CD8+ cytotoxic T-lympho-
cyte (CTL) cells can also hinder metastatic outgrowth, as previ-
ously shown by others (Eyles et al., 2010). What is certain is
that the inhibition of metastasis observed in our mouse model
can be ascribed to several factors and functions derived by
GS-deficient, M1-repolarized TAMs (Pollard, 2004; Rolny et al.,
2011).
It is worth noting that GS expression significantly senses
nutrient deprivation because its expression level is under the
control of FOXO3A (van der Vos et al., 2012). We confirm that
M2-polarized macrophages under conditions of glutamine star-
vation enhance GS expression compared with those grown in
high-nutrient medium, as already described for other cellular
models (van der Vos et al., 2012). M0 macrophages (which
weakly express GS) significantly increase GS protein levels
following starvation, and this event is sufficient to skew cells to-
ward an M2-like phenotype without any further cytokine treat-
ment, in line with the role of nutrient deprivation in modifying
the phenotype of macrophages, as described previously (O’Neill
and Hardie, 2013). More interestingly, starvation in M0 macro-
phages promotes glutamine secretion, which is sustained by
the upregulation of the cellular glutamine transporters. This
clearly suggests that GS expression (which is enhanced under
starved conditions) not only induces an M2-like polarization of
macrophages but may also promote glutamine secretion for
use by other cells.
In conclusion, our data suggest a functional role of glutamate-
to-glutamine conversion in M2 macrophages that is relevant for
the promotion of their immunosuppressive and proangiogenic
state, which is ultimately relevant for metastasis formation. The
present work highlights the role of metabolism rewiring as a
way tomanipulate macrophage functions, suggesting the impor-
tance of metabolic immunotherapeutic strategies in the fight
against cancer.
EXPERIMENTAL PROCEDURES
More detailed methods are described in the Supplemental Experimental
Procedures.
1662 Cell Reports 20, 1654–1666, August 15, 2017
(legend on next page)
Cell Reports 20, 1654–1666, August 15, 2017 1663
Animals
Experiments with control andGS cKOmicewere obtained from about 8-week-
old gender- and age-matched C57BL/6 littermates raised in a strictly con-
trolled environment. Colony-stimulating factor receptor 1 (CSF1R)-CreERT
transgenic mice (CSF1R-CreERTTg/WT), provided by J. Pollard (University of
Edinburgh, UK), in which a tamoxifen-induced Cre is under the transcriptional
control of the human CSF1R promoter, were crossed with GS-floxed mice
(GSL/L). The colony was bred by intercrossing GSL/L;CSF1R-CreERTTg/WT
with GSL/L;CSF1R-CreERTWT/WT mice or GSL/L;CSF1R-CreERTTg/WT with
GSL/WT;CSF1R-CreERTTg/WT mice. All mice were treated with intraperitoneally
(i.p.) injected tamoxifen (1 mg/mouse/day) for 5 days before subcutaneous im-
plantation of LLC cancer cells. Tamoxifen-treated GSL/L;CSF1R-CreERTTg/WT
mice were designated GS cKO mice, whereas GSL/L;CSF1R-CreERTWT/WT
mice or GSL/WT;CSF1R-CreERTTg/WT mice were used as control mice and de-
noted as WT or heterozygous (HET), respectively. Construction of targeting
vectors and pup genotyping were performed as reported previously (He
et al., 2010). 1 3 106 LLC adherent growing murine cells were injected
subcutaneously. Volumes were measured three times a week using the
formula V = p 3 d2 3 D/6, where d is the minor tumor axis and D is the major
tumor axis. At the end stage, tumorweight was registered, and lungmetastasis
nodules were counted after intratracheal injection of 15% India ink solution
(Finisguerra et al., 2015). Housing and all experimental animal procedures
were approved by the Institutional Animal Care and Research Advisory Com-
mittee of the KU Leuven.
Cell Isolation and Culture
Human monocytes were obtained from healthy blood donor buffy coats under
an institutional review board-approved protocol and isolated with CD14
MicroBeads (Miltenyi Biotec) as described previously (Palmieri et al., 2015).
After differentiation, macrophages were stimulated with LPS/IFNg (for M1 po-
larization), IL-4, IL-10, or a combination of both IL-4 and IL-10 (for M2 polari-
zation). Experiments of inhibition were performed using 1 mM MSO, an irre-
versible inhibitor of GS, 1 hr before adding cytokines for activation. When
starved, macrophages were transferred, for the last 36 hr of their differentia-
tion, into RPMI medium containing 2mM glucose and 0.3 mM glutamine. Cells
were then stimulated with cytokines at the indicated times.
RNA and Protein Expression Analysis
RNA isolation and subsequent qRT-PCR analysis as well as protein extrac-
tion and western blot analysis were performed as described before (Menga
et al., 2015; Palmieri et al., 2014; Prosniak et al., 2013). Glutamine quantifica-
tion by liquid chromatography-tandem mass spectrometry (LC-MS/MS) was
achieved as described previously (Palmieri et al., 2014), whereas GS enzy-
matic activity was measured as indicated (Castegna et al., 2011).
13C Tracing Experiments
For metabolite analysis using mass spectrometry, cells were cultured for 24 hr
in glucose- and glutamine-free DMEM with dialyzed fetal bovine serum (FBS),
and the appropriate tracer was added. [U-13C]-glutamine and [U-13C]-glucose
were from Sigma-Aldrich and Cambridge Isotopes Laboratories, respectively.
Samples were extracted and analyzed as described in the Supplemental
Experimental Procedures.
HIF1a-Responsive Luciferase Reported Expression
To express an inducible HIF-responsive firefly luciferase reporter, a pRRL-
H3RO (Leite de Oliveira et al., 2012) plasmid vector was used. Human macro-
phages (4 3 104) were seeded in a 96-well plate in RPMI and 10% FBS as
described before and transfected on day 7 of differentiation After 24 hr, cells
were stimulated with LPS/IFNg or IL-10 with and/or without 2 hr of pre-incuba-
tion with 1 mMMSO and 5 mM acriflavine (ACF). After 16 hr, the same amount
of protein extract was read in a luminometer (Takeda et al., 2011).
CD4+ and CD8+ T Cell Purification and Expansion and CD8+
Transmigration Assay
CD4+ andCD8+ cells were purified bymagnetic assisted cell sorting (MACS) as
described elsewhere (Barik et al., 2013), activated, expanded, and co-cultured
with M2 and M2 plus MSO. Proliferation was measured, and suppression was
calculated as in the Supplemental Experimental Procedures.
Migration of CD8+ cells in response to macrophage-secreted factors was
assessed by using Transwell permeable supports with a 5-mmporous polycar-
bonate membrane (Costar). LPS/IFNg and IL-10 stimulated macrophages with
or without MSO and CD8+ cells were incubated for 3 hr at 37C, and migrated
cells were collected and counted under a microscope (Finisguerra et al., 2015)
as described in the Supplemental Experimental Procedures.
EC Capillary Formation
2 3 105 human differentiated macrophages were embedded in Matrigel (BD
Biosciences). After 4 hr of preconditioning, 13 104 human umbilical vein endo-
thelial cell (HUVEC) fluorescently labeled with PKH-26 (Sigma-Aldrich) were
added to the Matrigel. After 4 hr, HUVEC capillary formation was analyzed
by measuring the number and length of branches using ImageJ software.
Statistical Analysis
Data entry and all analyses were performed in a blinded fashion. Results are
shown as means ± SEM. Statistical significance was calculated by two-tailed
unpaired t test or ANOVA test with Tukey post hoc test and considered statis-
tically significant as follows: *p < 0.05, **p < 0.001, ***p < 0.0001.
Figure 7. Genetic Deletion of GS in TAMs Induces an M1-like Phenotype and CTL Accumulation, Inhibits Metastasis, and Induces Vessel
Normalization
(A) Efficiency and specificity of genetic deletion in cKOmicemeasured by qRT-PCR onGSmRNA in F4/80+macrophages and F4/80 splenocytes, freshly sorted
after 5-day in vivo treatment with tamoxifen (n = 3).
(B andC) Subcutaneous LLC tumor growth over time (B) and end-stage tumor weight (C) in wild-type (WT) andmacrophage-specific knockout (cKO)mice (pool of
3 independent experiments, total n = 25).
(D) Number of lung metastases and lung metastatic index (the number of lung metastatic nodules divided by the corresponding tumor weight) in WT and
macrophage-specific knockout (cKO) mice (pool of 3 independent experiments, total n = 25).
(E–G) FACS quantification of total F4/80+ TAMs (E), M1-like MHC class IIhigh TAMs (F), and CD206-positive TAMs (G) in WT and macrophage-specific knockout
(cKO) mice (n = 4).
(H–J) Evaluation of glutamine (H), glutamate (I), and succinate (J) in WT and macrophage-specific knockout (cKO) mice (n = 4).
(K–N) qRT-PCR quantification of CCL17 (K), CCL22 (L), MRC1 (M), AND ARG1 (N) in WT and macrophage-specific knockout (cKO) mice (n = 4).
(O) FACS quantification of CD8+ cytotoxic T cells in WT and macrophage-specific knockout (cKO) mice (n = 4).
(P andQ) Quantification (P) and representative images (Q) of the CD31+ tumor vessel area inWT andmacrophage-specific knockout (cKO)mice (n = 8). The vessel
area was calculated by the percentage of CD31 area per field.
(R and S) Quantification (R) and representative images (S) of pimonidazole (PIMO)+ tumor hypoxic areas in WT and macrophage-specific knockout (cKO) mice
(n = 8).
(T and U) Quantification (T) and representative images (U) of leaky vessels in WT and macrophage-specific knockout (cKO) mice, measured as the percentage of
endoglin/CD105+ vessels surrounded by lakes of TER119+ red blood cells over the total number of vessels (n = 8). In each immunofluorescence quantification,
n represents the number of animals. Six images per tumor were analyzed.
Scale bars, 100 mm. All graphs show mean ± SEM. *p < 0.05 versus the WT. See also Figures S1 and S2.
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